Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antispasmin is a brand name for a line of antispasmodic medications developed and marketed by the Indian pharmaceutical company Stadmed. The most common formulation is a combination tablet containing **dicycloverine hydrochloride** (also known as dicyclomine) and **paracetamol** (acetaminophen). Dicycloverine is a tertiary amine that functions as a muscarinic receptor antagonist, providing relief from smooth muscle spasms in the gastrointestinal tract, biliary tract, and ureters. Paracetamol is included to provide analgesic effects for associated pain. Antispasmin is indicated for the treatment of functional bowel disorders, irritable bowel syndrome (IBS), and various forms of colic (biliary, renal, and intestinal). It is also available in other dosage forms, including injections and syrups, which typically contain dicycloverine as the sole active ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antispasmin.